Phil

[Phil @dieuphil]

$BCTX Briacell

Conclusion: If BCTX delivers successful Phase 3 interim data, a buyout offer below $30.00 would likely be rejected by shareholders as "undervaluing" the asset. A realistic "fair value" buyout in a competitive bidding war would target the $45–$75 range.

[Phil @dieuphil]

@ScienceofPD @lochossian @CharlesMBrenner @ParkinsonDotOrg @APDAParkinsons
Last update on NoPark P3 trial for Parkinson's Disease using NR was Dec 2025. Results soon !

"At a conference in December, someone asked Dr. Tzoulis whether the NoPark showed that NR was efficacious. He responded: You will know in early 2026."

[Phil @dieuphil]

@ScienceofPD @lochossian @CharlesMBrenner , do you have a current estimate on when NOPARK Phase 3 results are anticipated to be published ? The study was originally expected to be published by end of 2025.

[Phil @dieuphil]

#NADTwitter #TeamNR #Alzheimers @truniagen @ChromaDex @ScienceOfNAD @RaisingNad @alzassociation @alzheimerssoc @AlzResearchUK

Tru Niagen NR Nicotinamide Riboside

Promising development in Alzheimer's Disease using NR Tru Niagen Supplement from Chromadex

https://t.co/YYl8XUxAwf

[Phil @dieuphil]

#NADtwitter #teamNR #NMN @truniagen @ScienceOfNAD @RaisingNad Amazon ban on NMN. Not to worry! Tru Niagen (over 4 million bottles sold) NR (Nicotinamide Riboside) is more efficient than NMN, with a huge safety dossier. 5 reasons NMN Users should consider switching to NR.

[Science of NAD @ScienceOfNAD]

Amazon's new ban hurts NMN sellers, but not consumers, because no study says that NMN performs better than NR https://t.co/1YRfdy2R16

[Phil @dieuphil]

Tru Niagen Chromadex

[Charles Brenner, PhD @CharlesMBrenner]

yes indeed

[Charles Brenner, PhD @CharlesMBrenner]

btw @ChromaDex was also asked to provide @truniagen to all pts who completed #NADPARK Parkinson’s RCT bc the effects were so promising

#NADtwitter

[Phil @dieuphil]

#Alzheimers @CharlesMBrenner @Mardinoglu

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
https://t.co/yY9tbdUuOT

[Phil @dieuphil]

@CharlesMBrenner @ChromaDex @truniagen @ScienceOfNAD @NIHAging @hubermanlab Hope these remarkable results are disseminated to major news organizations. This is very encouraging progress in the search for a viable treatment for Alzheimer’s and NR is a critical component.

[Adil Mardinoglu @Mardinoglu]

The result of our Phase 2 #AlzeheimerDisease clinical study, where we tested the effect of the Combined Metabolic Activators is now published at #TranslationalNeurodegeneration. Many thanks to everyone who participated in the study.

[Charles Brenner, PhD @CharlesMBrenner]

truly awesome to see this out

#teamNR
#NADtwitter

[niagenbioscience @niagenbio]

Read more here: https://t.co/XEgWYpPpAD

[niagenbioscience @niagenbio]

Welcome Dr. Vilhelm Bohr, the newest addition to our scientific advisory board! One of the world’s leading researchers on aging, he has served as chief of the laboratory of molecular genetics at the National Institute on Aging, which is part of the National Institutes of Health.

[Eija Pirinen @pirinenlab]

I am excited to share our findings from a clinical trial performed together with @DrPietilainen. We studied the long-term effect of nicotinamide riboside (NR) on mitochondrial biogenesis and metabolic health in BMI-discordant identical twin pairs. https://t.co/P6v1iuqsWJ

[Phil @dieuphil]

@snetram @hubermanlab @CharlesMBrenner @BradStanfieldMD @ChromaDex @NIHAging

This new paper in collaboration with NIA appears to support Christopher Martens, Ph.D. preliminary findings on NR and Alzheimer’s in which further clinical trials are being conducted.

https://t.co/Cv14z3qW9B

[Phil @dieuphil]

@snetram @CharlesMBrenner Christopher Martens Ph.D. has done some outstanding research work. Some exciting research ahead.

[Phil @dieuphil]

@snetram Thank you Sir !

[Phil @dieuphil]

@snetram @snetram Great work ! Could you provide a layperson's synopsis of overall results ? It will help folks understand the significance of your findings. Thank you.

[Charles Brenner, PhD @CharlesMBrenner]

University backtracks on inflammatory headline but still misses the mark according to CRN https://t.co/E3Qf6Uy2hA